{
    "path": [
        601160000,
        101000002,
        601410000,
        1008030000,
        800000000
    ],
    "contexts": [
        "\"delivered dose\" means, in relation to: (a) metered dose preparations - the dose delivered to the patient in a single actuation or delivery; and (b) powders for inhalation - the dose delivered from the inhaler in a single delivery;",
        "(2) The purpose of the label on a medicine is to provide information about the medicine such as its identity, potency, content, storage, expiry date, dose, directions for use, sponsor details and registration\/listing status. Labels on medicines can also include other information not required by this Order but which may be required by other legislation or for commercial purposes such as the sponsor\u2019s logo.",
        "\"name of an excipient\" means the name of the excipient that is accepted for inclusion in the Australian Approved Names List;",
        " (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.",
        " 8 Information to be included on the label"
    ]
}
{
    "path": [
        801000000,
        302000000,
        1003000000,
        903030000,
        903010000
    ],
    "contexts": [
        " (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include:",
        "(2) To avoid doubt, this Order will apply to the following medicines:",
        " (3) Homoeopathic medicines Where all the active ingredients in a medicine are homoeopathic preparations, the main label on the container and the main label on the primary pack (if any) must, in addition to the requirements referred to in sections 8 and 9 above, include a statement to the effect that the medicine is a homoeopathic medicine in text size that is not less than 50% of the text size of the name of the medicine and (in any event) not less than 2 millimetres.",
        " (c) if the medicine is: (i) supplied in either a small or a medium container; and (ii) contains multiple active ingredients then, in relation to compliance of the label with paragraph 9(3)(a), the names of the multiple active ingredients and their quantities may be presented together on a continuous line, or lines, of text.",
        " (a) appear as a cohesive unit by the placing of the name and quantity of each active ingredient together on separate lines of text either (i) immediately below the name of the medicine; or (ii) where the trademark of the medicine might be disrupted or obscured, adjacent to the name of the medicine; and"
    ]
}
{
    "path": [
        804020000,
        910000000,
        101000006,
        1001000000,
        1007000000
    ],
    "contexts": [
        " (b) the name(s) of all active ingredients in the medicine; and",
        " (10) Subsection 9(9) does not apply:",
        "(6) Guidelines to assist in the design of medicine labels are available on the Therapeutic Goods Administration website (http:\/\/www.tga.gov.au).",
        " (1) Preparations for ophthalmic use In addition to the requirements of sections 8 and 9 above, if a medicine is a preparation for ophthalmic use, the label on the container and on the primary pack or, where subsection 10(7) applies, the primary pack, must include:",
        " (7) Small containers If:"
    ]
}
{
    "path": [
        905010000,
        901020000,
        501170000,
        910020000,
        911000000
    ],
    "contexts": [
        " (a) two or more active ingredients; and",
        " (b) the name(s) of all active ingredients in the medicine; and",
        "(q) blood products under Item 13 that are described under paragraphs (a) and (b) under the heading \u2018HUMAN BLOOD PRODUCTS\u2019 in Appendix A to the Poisons Standard.",
        " (b) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2\u2014after 30 April 2026; or",
        " (11) An active ingredient specified in Part 1 of Schedule 2, either alone or in combination with any other descriptors, may be included on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2026."
    ]
}
{
    "path": [
        802010000,
        601130000,
        804060000,
        1005000000,
        900000000
    ],
    "contexts": [
        " (a) Subject to paragraphs (b), (c) and (d), where the medicine is registered goods, the critical health information must be displayed on the label of the primary pack in a tabulated form.",
        "\"composite pack\" has the same meaning as in the Act;",
        " (f) the name of the sponsor or distributor, or a registered trademark if it readily identifies the sponsor or distributor of the medicine.",
        " (5) Sunscreen preparations If:",
        " 9 Information to be included on the main label"
    ]
}
{
    "path": [
        601260000,
        601210000,
        802060000,
        908030000,
        906020000
    ],
    "contexts": [
        "\"herbal material\" means a plant or part of a plant (defined by its botanical scientific name according to the binominal nomenclature system, including author, and the plant part), whether fresh or dried, that is whole, fragmented, cut or ground;",
        "\"excipient\", in relation to a medicine, means an ingredient of the medicine other than the active ingredient;",
        " (f) The presentation of the critical health information, and any information mentioned in paragraphs 8(2)(c), 8(2)(d) or 8(2)(e) that is included, must be presented in black or other dark coloured texts, using only one colour, on a white or other contrasting background.",
        " (c) (i) the total number of active ingredients in the different formulations in the composite pack or medicine kit are to be counted; and (ii) if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately, for the purposes of determining if paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit; and",
        " (b) if there are four or more active ingredients in the medicine - the name of every active ingredient, together with the quantity or proportion of every active ingredient, may appear on a side panel or side label or on a rear panel or rear label."
    ]
}
{
    "path": [
        601490000,
        1100000000,
        702000000,
        910030000,
        913000000
    ],
    "contexts": [
        "\"registration number\" means the combination of numbers and letters that is required to be included on the label of medicines in a manner described in regulation 15 of the Regulations;",
        " 11 How information is to be expressed",
        " (2) The information required by this Order to be included on a label or labels must:",
        " (c) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2\u2014after 30 April 2028. Note: The minimum text size for active ingredients on labels of small containers is less than 2.5 millimetres and specified elsewhere in this Order.",
        " (13) An active ingredient specified in Part 2 of Schedule 2, either alone or in combination with any other descriptors, may be included on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2028."
    ]
}
{
    "path": [
        1103000000,
        601460002,
        802030000,
        905030000,
        901030000
    ],
    "contexts": [
        " (3) Expression of quantity or proportion of active ingredients for homoeopathic preparations The label on the container and on the primary pack of a medicine that contains a homoeopathic preparation must include:",
        "(b) where the medicine is: (i) a solid or semi-solid - the stated weight in the container; (ii) a liquid - the stated volume of fill in the container; (iii) a pressurised metered-dose preparation or dry powder inhaler - the stated number of deliverable doses in the container; (iv) a non-pressurised metered dose preparation - the minimum number of deliverable doses in the container;",
        " (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order.",
        " (c) if the medicine is intended to be, or is, registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.",
        " (c) the quantity or proportion of all active ingredients in the medicine; and"
    ]
}
{
    "path": [
        401020020,
        1007080000,
        901010000,
        805000000,
        801000000
    ],
    "contexts": [
        "(ii) Therapeutic Goods Order No. 69 - General Requirements for Labels for Medicines 2017 (TGO 69 (2017)), on or after 1 July 2017.",
        " (h) the quantity of the medicine in the container; and",
        " (a) the name of the medicine; and",
        " (5) If the container is enclosed in a delivery device such that it cannot be removed, the information required on its label under subsection 8(1) must be applied on the delivery device and not the container.",
        " (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include:"
    ]
}
{
    "path": [
        601260000,
        804040000,
        1010010000,
        302020000,
        500000000
    ],
    "contexts": [
        "\"herbal material\" means a plant or part of a plant (defined by its botanical scientific name according to the binominal nomenclature system, including author, and the plant part), whether fresh or dried, that is whole, fragmented, cut or ground;",
        " (d) the batch number of the medicine preceded by the batch number prefix; and",
        " (a) Subject to paragraph (b), if: (i) a medicine is contained in a plastic ampoule; and (ii) the capacity of the container of the medicine in the plastic ampoule is 8 millilitres or less; and (iii) two or more ampoules are attached to a connecting strip; and (iv) the ampoules and their connecting strip are enclosed in a primary pack that complies with the requirements of this Order, then the information required by this Order to appear on the label of the container of the medicine may be divided between the ampoule and the connecting strip.",
        "(b) medicines exempt from the listing and registration requirements, other than those specified in section 5 of this Order.",
        "5 Exemptions \u2013 Medicines to which this Order does not apply "
    ]
}
{
    "path": [
        601570000,
        300000000,
        601460003,
        1102080000,
        1102030000
    ],
    "contexts": [
        "\"stated volume of fill\" means the volume of medicine that the container is specified by the sponsor to contain;",
        "3 Application - Therapeutic goods to which this Order applies",
        "(c) where the medicine is a medicine of any of the kinds referred to in paragraph (b) and the medicine consists of a number of identical containers within the primary pack \u2013 the number of containers (e.g. 5 x 10 mL vials);",
        " (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.",
        " (c) subject to paragraph (d) below, if the medicine is a liquid for ingestion: (i) as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid; or (ii) in the case where the liquid for ingestion is one of a series of strengths containing the same active ingredient \u2013 as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume. Example: Where the dose volume is 5 mL, and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labelled as 5 mg in 5 mL and 25 mg in 5 mL, respectively."
    ]
}
{
    "path": [
        914000000,
        501150000,
        601460002,
        907030000,
        802000000
    ],
    "contexts": [
        " (14) To avoid doubt, an active ingredient specified in Part 2 of Schedule 2 must be included on the main label of a medicine containing that ingredient in accordance with the Australian Approved Names List for medicine released for supply on or after 1 May 2028.",
        "(o) a medical gas; or",
        "(b) where the medicine is: (i) a solid or semi-solid - the stated weight in the container; (ii) a liquid - the stated volume of fill in the container; (iii) a pressurised metered-dose preparation or dry powder inhaler - the stated number of deliverable doses in the container; (iv) a non-pressurised metered dose preparation - the minimum number of deliverable doses in the container;",
        " (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or",
        " (2)"
    ]
}
{
    "path": [
        907040000,
        801150000,
        601270000,
        601150000,
        801100000
    ],
    "contexts": [
        " (d) if subsection 8(2) applies and the medicine: (i) includes one or more active ingredients, the name of which includes descriptors (for example chemical salts or hydration states) that are not therapeutically relevant; and (ii) the name and quantity or proportion of each of those active ingredients is displayed in accordance with subsection 8(2), then the name of the therapeutically active moiety(ies) of the active ingredient may be displayed on the main label on the primary pack, instead of the name of the active ingredient, if: (iii) this is in a text size of not less than 3.0 millimetres; and (iv) no quantity or proportion information is displayed for any of the active ingredients in the medicine.",
        " (o) if the medicine is contained in an ampoule, a statement of the approved route of administration for the medicine, such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration.",
        "\"herbal preparation\" means an ingredient that is the result of the processing of a herbal material;",
        "\"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
        " (j) where: (i) a substance or substance within the group of substances referred to in Column 1 of Schedule 1 to this Order is present in the medicine; (ii) the circumstances as set out in Column 2 of Schedule 1 exist in relation to such a substance or no circumstances are set out in Column 2; and (iii) the medicine is intended to be administered via any one or more of the route(s) of administration referred to in Column 3 of Schedule 1, then: (iv) a statement: (A) indicating that the medicine contains the substance expressed using the Name stated in Column 4 of Schedule 1; and (B) where any of the circumstances and requirements set out in Column 2 of Schedule 1 exist in relation to the substance \u2013 a statement of the kind referred to as a \u2018requirement\u2019 in that Column (if any); and"
    ]
}
{
    "path": [
        1008030000,
        601410000,
        905030000,
        802050000,
        802030000
    ],
    "contexts": [
        " (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.",
        "\"name of an excipient\" means the name of the excipient that is accepted for inclusion in the Australian Approved Names List;",
        " (c) if the medicine is intended to be, or is, registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.",
        " (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details.",
        " (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order."
    ]
}
{
    "path": [
        1007030000,
        901050000,
        1007120000,
        1009010000,
        900000000
    ],
    "contexts": [
        " (c) the name of the medicine; and",
        " (e) the quantity of the medicine; and",
        " (l) if the medicine is contained in an ampoule - a statement of the approved route of administration for the medicine, such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration of the medicine; and",
        " (a) Subject to paragraph (b), if: (i) a medicine consists of individual dosage units such as tablets, capsules, pills, pastilles, cachets, lozenges, pessaries, suppositories or single doses of powder; and (ii) two or more dosage units are individually enclosed in a strip, blister or dial dispenser pack such that the dosage units can only be extracted individually; and (iii) the strip, blister or dial dispenser pack is enclosed in a primary pack, the label of which complies with sections 8 and 9, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iv) the name of the medicine; and (v) the name(s) of all active ingredients in the medicine; and (vi) the quantity or proportion of all active ingredients in the medicine; and (vii) the batch number of the medicine preceded by the batch number prefix; and (viii) the expiry date of the medicine preceded by the expiry date prefix; and (ix) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
        " 9 Information to be included on the main label"
    ]
}
{
    "path": [
        802030000,
        601260000,
        1008020000,
        601150000,
        801120000
    ],
    "contexts": [
        " (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order.",
        "\"herbal material\" means a plant or part of a plant (defined by its botanical scientific name according to the binominal nomenclature system, including author, and the plant part), whether fresh or dried, that is whole, fragmented, cut or ground;",
        " (b) If: (i) the medicine consists only of pastilles or lozenges; and (ii) each dosage unit is enclosed in an unsealed individual wrapper; and (iii) each dosage unit is, after being so wrapped, enclosed in a primary pack that complies with sections 8 and 9, then, in relation to compliance of the label for each individual wrapper with sections 8 and 9, it shall be sufficient if the name of the medicine is displayed.",
        "\"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
        " (l) directions for use of the medicine except where: (i) the dose of the medicine is usually determined for each individual patient by a health professional authorised under a law of a State or Territory to determine the dose; or (ii) there is insufficient space on the label of either the container or the primary pack, or both, to include directions for use, and: (A) those directions for use are set out in a package insert provided in the primary pack of the medicine; and (B) a statement is included on whichever label on the container, or the primary pack, or both, that does not set out the directions for use itself, that those directions are set out in the package insert; and"
    ]
}
{
    "path": [
        1104000000,
        904000000,
        802050000,
        903020000,
        1102090000
    ],
    "contexts": [
        " (4) Permitted statements of storage temperature conditions For the purposes of this Order, the following statements of storage temperature conditions are permitted: (i) \u2018Store below \u201318oC (Deep freeze)\u2019; (ii) \u2018Store below \u20135oC (Freeze)\u2019; (iii) \u2018Store at 2oC to 8oC (Refrigerate. Do not freeze)\u2019; (iv) \u2018Store below 25oC\u2019; (v) \u2018Store below 30oC\u2019; (vi) for a medicine that is, or is intended to be, registered goods, any other storage temperature conditions as specified in the approved product details in relation to the medicine.",
        " (4) All text required by this Order to be on the main label must be oriented in the same direction.",
        " (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details.",
        " (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;",
        " (i) In addition to the requirements of paragraphs 11(2)(a) \u201311(2)(g), the following requirements apply in the circumstances specified in the following subparagraphs: (i) where the active ingredient is a herbal material, such as a dry, fresh, milled or powdered herb, as the weight of the herbal material; except where standardisation is claimed on the label, then the minimum dry or fresh weight of herbal material and also the quantity of standardised constituents(s) in the herbal material; (ii) where the active ingredient is a herbal preparation, as the dry or fresh weight of the herbal material from which the preparation was derived except: (A) where standardisation of the herbal preparation is claimed on the label, then, the minimum dry or fresh weight of herbal material from which the preparation is derived and the quantity of standardised constituents(s) in the herbal preparation; or (B) where the active ingredient is a herbal preparation that is an essential oil; (iii) where the active ingredient is an enzyme \u2013the activity unit as specified in Column 1 of Schedule 3 to this Order in relation to a particular enzyme set out in Column 3 of that Schedule; (iv) for preparations containing Vitamin A or a derivative of Vitamin A - as the quantity or proportion of Vitamin A expressed in terms of microgram retinol equivalents; (v) for preparations containing biological organisms - as the number of organisms present per metric unit for liquids and powders and as the number of organisms present per dosage unit for other dosage forms;"
    ]
}
{
    "path": [
        1105010000,
        801130000,
        1102100000,
        903020000,
        1102080000
    ],
    "contexts": [
        " (a) on the same line of text - between the approved name of the active ingredient that is a vitamin and the quantity of that active ingredient; or",
        " (m) if the medicine requires some preparation, such as dissolving, suspending, diluting or reconstituting before use - instructions for its preparation and, where relevant, a statement of the conditions of storage and the maximum period of storage between preparation and use, except where: (i) there is insufficient space on the label of either the container or the primary pack, or both, to include this information; and (ii) this information is set out in a package insert provided in the primary pack of the medicine; and (iii) a statement is included on whichever label on the container or the primary pack, or both, that does not set out the information itself, that this information is set out in the package insert; and",
        " (j) for any other medicines: (i) where the medicine is a liquid and includes an active ingredient which is a liquid - as the appropriate amount of the active ingredient, either by weight or volume, in a stated volume of the medicine; (ii) where the medicine is a liquid and includes an active ingredient which is a solid - as the weight of active ingredient in a stated volume of the medicine; (iii) where the medicine is a liquid and includes an active ingredient which is a gas - as the weight of the active ingredient in a stated volume of the medicine; (iv) where the medicine is a solid or semi-solid and includes an active ingredient which is a liquid - as the appropriate amount of the active ingredient, either by weight or volume, in a stated weight of the medicine; (v) where the medicine is a solid or semi-solid and includes an active ingredient which is a solid - as the weight of the active ingredient in a stated weight of the medicine.",
        " (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;",
        " (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation."
    ]
}
{
    "path": [
        601100000,
        601270000,
        1102000000,
        1009010000,
        800000000
    ],
    "contexts": [
        "\"Certificate of Listing\", in relation to a medicine, means the certificate given to the applicant for listing of the medicine under subsection 26(4) or subsection 26A(9) of the Act in relation to that medicine;",
        "\"herbal preparation\" means an ingredient that is the result of the processing of a herbal material;",
        " (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed:",
        " (a) Subject to paragraph (b), if: (i) a medicine consists of individual dosage units such as tablets, capsules, pills, pastilles, cachets, lozenges, pessaries, suppositories or single doses of powder; and (ii) two or more dosage units are individually enclosed in a strip, blister or dial dispenser pack such that the dosage units can only be extracted individually; and (iii) the strip, blister or dial dispenser pack is enclosed in a primary pack, the label of which complies with sections 8 and 9, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iv) the name of the medicine; and (v) the name(s) of all active ingredients in the medicine; and (vi) the quantity or proportion of all active ingredients in the medicine; and (vii) the batch number of the medicine preceded by the batch number prefix; and (viii) the expiry date of the medicine preceded by the expiry date prefix; and (ix) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
        " 8 Information to be included on the label"
    ]
}
{
    "path": [
        1006080000,
        100000000,
        1006070000,
        907020000,
        802000000
    ],
    "contexts": [
        " (h) any warning statements that relate to any of the medicines within the kit;",
        "About this compilation ",
        " (g) an expiry date for the kit, being the earliest expiry date of the medicines within the kit, preceded by the expiry date prefix;",
        " (b) where the medicine contains four or more active ingredients and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or",
        " (2)"
    ]
}
{
    "path": [
        914000000,
        601070000,
        601400000,
        908040000,
        907000000
    ],
    "contexts": [
        " (14) To avoid doubt, an active ingredient specified in Part 2 of Schedule 2 must be included on the main label of a medicine containing that ingredient in accordance with the Australian Approved Names List for medicine released for supply on or after 1 May 2028.",
        "\"batch number prefix\" means the prefix which precedes the batch number and has the following characteristics: (a) clearly indicates that the information following the prefix is the batch number; and (b) is in the following form: \\\"BATCH NUMBER\\\", \\\"BATCH NO.\\\", \\\"BATCH\\\", \\\"B\\\", \\\"(B)\\\", \\\"B\/N\\\", \\\"LOT NUMBER\\\", \\\"LOT NO.\\\", or \\\"LOT\\\", or words or symbols to this effect, including a mixture of lower and upper case letters;",
        "\"name of an active ingredient\" means: (a) the name of the active ingredient that is accepted for inclusion in the Australian Approved Names List; or (b) where the ingredient is a homoeopathic preparation: (i) either the name of the active ingredient, or the substance from which the dilution was prepared, that is accepted for inclusion in the Australian Approved Names List, together with a statement of the homoeopathic potency; or (ii) until such time as a name is accepted for inclusion in the Australian Approved Names List, a traditional homoeopathic name in full or as traditionally abbreviated with a statement of the homoeopathic potency;",
        " (d) the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit.",
        " (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then:"
    ]
}
{
    "path": [
        903030000,
        901020000,
        501120000,
        903020000,
        1105000000
    ],
    "contexts": [
        " (c) if the medicine is: (i) supplied in either a small or a medium container; and (ii) contains multiple active ingredients then, in relation to compliance of the label with paragraph 9(3)(a), the names of the multiple active ingredients and their quantities may be presented together on a continuous line, or lines, of text.",
        " (b) the name(s) of all active ingredients in the medicine; and",
        "(l) supplied, in the course of treating a patient, by a health professional in the lawful practice of his or her profession; or",
        " (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;",
        " (5) Inclusion of common names of vitamins Where a medicine contains an active ingredient that is a vitamin, then the word \u2018vitamin\u2019, or any suitable unambiguous abbreviation of the word vitamin, together with the common name of that vitamin, may appear on a main label of the medicine either:"
    ]
}
{
    "path": [
        1102060000,
        601430103,
        401020010,
        1102070000,
        1102060000
    ],
    "contexts": [
        " (f) for pressurised metered dose inhalers, dry powder inhalers and other metered dose products such as nasal sprays, the quantity of the active ingredient is: (i) the quantity delivered per actuation; or where the Secretary, when registering the medicine, has accepted that the dose of products containing those active ingredients was clinically established as the metered dose, then: (ii) the quantity metered per actuation;",
        "(iii) the dosage form (except where this is integral to differentiate medicines from other medicines);",
        "(i) Therapeutic Goods Order No. 69 General requirements for labels for medicines (TGO 69), up until 30 June 2017 (inclusive); or",
        " (g) for preparations applied to the skin and mucous membranes, other than those covered by paragraph (f) - as a percentage expressed in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate;",
        " (f) for pressurised metered dose inhalers, dry powder inhalers and other metered dose products such as nasal sprays, the quantity of the active ingredient is: (i) the quantity delivered per actuation; or where the Secretary, when registering the medicine, has accepted that the dose of products containing those active ingredients was clinically established as the metered dose, then: (ii) the quantity metered per actuation;"
    ]
}
{
    "path": [
        501000000,
        903000000,
        1006030000,
        301000000,
        500000000
    ],
    "contexts": [
        " This Order does not apply to a medicine that is:",
        " (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must:",
        " (c) the name of each of the medicines within the kit and its dosage form;",
        "(1) Subject to sections 4 and 5, this Order applies to medicines supplied or for supply in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91 \u2013 Standard for labels of prescription and related medicines.",
        "5 Exemptions \u2013 Medicines to which this Order does not apply "
    ]
}
{
    "path": [
        903020000,
        601440000,
        601450000,
        1007000000,
        1001000000
    ],
    "contexts": [
        " (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;",
        "\"Poisons Standard\" means the current Poisons Standard as defined in section 52A of the Act;",
        "\"primary pack\" has the same meaning as in the Act;",
        " (7) Small containers If:",
        " (1) Preparations for ophthalmic use In addition to the requirements of sections 8 and 9 above, if a medicine is a preparation for ophthalmic use, the label on the container and on the primary pack or, where subsection 10(7) applies, the primary pack, must include:"
    ]
}
{
    "path": [
        801070000,
        401020010,
        101000006,
        403000000,
        402000000
    ],
    "contexts": [
        " (g) the expiry date of the medicine, preceded by the expiry date prefix; and",
        "(i) Therapeutic Goods Order No. 69 General requirements for labels for medicines (TGO 69), up until 30 June 2017 (inclusive); or",
        "(6) Guidelines to assist in the design of medicine labels are available on the Therapeutic Goods Administration website (http:\/\/www.tga.gov.au).",
        "(3) Notwithstanding (1) and (2), medicines imported into or manufactured in Australia before 1 September 2020 but supplied by a person other than the sponsor after that date must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017).",
        "(2) On and from 1 September 2020, each medicine to which this Order applies must comply with the requirements specified in this Order."
    ]
}
{
    "path": [
        1006070000,
        914000000,
        801150000,
        1008030000,
        900000000
    ],
    "contexts": [
        " (g) an expiry date for the kit, being the earliest expiry date of the medicines within the kit, preceded by the expiry date prefix;",
        " (14) To avoid doubt, an active ingredient specified in Part 2 of Schedule 2 must be included on the main label of a medicine containing that ingredient in accordance with the Australian Approved Names List for medicine released for supply on or after 1 May 2028.",
        " (o) if the medicine is contained in an ampoule, a statement of the approved route of administration for the medicine, such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration.",
        " (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.",
        " 9 Information to be included on the main label"
    ]
}
{
    "path": [
        1100000000,
        1008010000,
        601360000,
        1103030000,
        1103020000
    ],
    "contexts": [
        " 11 How information is to be expressed",
        " (a) Subject to paragraph (b), if: (i) a medicine consists of individual dosage units such as tablets, capsules, pills, pastilles, cachets, lozenges, pessaries, suppositories, single doses of a powder, single doses of a liquid, or a transdermal patch; and (ii) each dosage unit is enclosed in an individual wrapper or blister, whether sealed or unsealed; and (iii) one or more dosage units are enclosed in a primary pack; and (iv) the label on the primary pack complies with sections 8 and 9, then, in relation to compliance of the label on each individual wrapper or blister with sections 8 and 9, it shall be sufficient if the following information is displayed: (v) the name of the medicine; and (vi) the name(s) of all active ingredients in the medicine; and (vii) the quantity or proportion of all active ingredients in the medicine; and (viii) the batch number of the medicine preceded by the batch number prefix; and (ix) the expiry date of the medicine preceded by the expiry date prefix; and (x) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
        "\"medicine\" has the same meaning as in the Act;",
        " (c) where paragraphs (a) and (b) do not apply- the quantity of the preparation in one millilitre or in one gram of the medicine",
        " (b) where all active ingredients of the medicine are homoeopathic preparations and are all included in the medicine in the same proportion - as \u2018Contains equal parts of ...\u2019 followed by the name of each active ingredient; or"
    ]
}
{
    "path": [
        1008030000,
        1102030000,
        401010000,
        601150000,
        801020000
    ],
    "contexts": [
        " (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.",
        " (c) subject to paragraph (d) below, if the medicine is a liquid for ingestion: (i) as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid; or (ii) in the case where the liquid for ingestion is one of a series of strengths containing the same active ingredient \u2013 as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume. Example: Where the dose volume is 5 mL, and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labelled as 5 mg in 5 mL and 25 mg in 5 mL, respectively.",
        "(a) the requirements specified in this Order; or",
        "\"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
        " (b) the name(s) of all active ingredients in the medicine; and"
    ]
}
{
    "path": [
        1009030000,
        401010000,
        601570000,
        802060000,
        802050000
    ],
    "contexts": [
        " (c) In addition to the requirements referred to in paragraphs 10(9)(a) and (b) as relevant, if each dosage unit is enclosed in the strip or blister such that an individual segment containing the dosage unit can be readily detached, then the following information must appear on the label of the strip or blister at least once in relation to every two dosage units: (i) for a medicine to which paragraph 10(9)(a) applies \u2013 the name of the medicine, the name(s) of all active ingredients in the medicine and the quantity or proportion of all active ingredients in the medicine; and (ii) for a medicine to which paragraph 10(9)(b) applies \u2013 the name of the medicine.",
        "(a) the requirements specified in this Order; or",
        "\"stated volume of fill\" means the volume of medicine that the container is specified by the sponsor to contain;",
        " (f) The presentation of the critical health information, and any information mentioned in paragraphs 8(2)(c), 8(2)(d) or 8(2)(e) that is included, must be presented in black or other dark coloured texts, using only one colour, on a white or other contrasting background.",
        " (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details."
    ]
}
{
    "path": [
        1007040000,
        601390000,
        102000001,
        1005000000,
        800000000
    ],
    "contexts": [
        " (d) the name(s) of all active ingredients in the medicine, unless there are four or more active ingredients; and the following information is displayed in a text size of not less than 1.5 millimetres:",
        "\"name and contact details\" in respect of a sponsor or distributor, means (a) the name of the sponsor or distributor and sufficient information to allow the sponsor or distributor to be uniquely identified so as to facilitate public contact on matters of complaint, use or general enquiry. The contact details must include information such as the city or suburb of the sponsors distributors principal place of business in Australia (not being a post office, cable, telegraphic or code address). The Australian telephone number, website or email address may also be included; or (b) where there has been a change in the sponsors or distributors name or contact details in the previous twelve months, the name and contact details of the previous sponsor or distributor;",
        "This Order is to be known as the Therapeutic Goods Order No. 92 - Standard for labels of non-prescription medicines.",
        " (5) Sunscreen preparations If:",
        " 8 Information to be included on the label"
    ]
}
{
    "path": [
        101000001,
        601120000,
        801060000,
        907030000,
        901030000
    ],
    "contexts": [
        "(1) This Order sets out what kinds of information are required to be included on the label of medicines of the kind described in section 3, and in what circumstances.",
        "\"complementary healthcare practitioner\" means a person described in paragraph 42AA(1)(c) of the Act;",
        " (f) the batch number of the medicine preceded by the batch number prefix; and",
        " (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or",
        " (c) the quantity or proportion of all active ingredients in the medicine; and"
    ]
}
{
    "path": [
        1004000000,
        802000000,
        1005020000,
        1007000000,
        900000000
    ],
    "contexts": [
        " (4) Formulations containing both homoeopathic preparations and non-homoeopathic ingredients Where a medicine contains active ingredients that are homoeopathic preparations, and other active ingredients that are not homoeopathic preparations, then, in addition to the requirements referred to in sections 8 and 9 above:",
        " (2)",
        " (b) is enclosed in a container with a capacity of not more than 25 millilitres, then, in relation to compliance with sections 8 and 9, it shall be sufficient if (i) the sun protection factor is displayed in a text size of not less than 1.5 millimetres; and (ii) all other information is displayed in a text size of not less than 1.0 millimetres.",
        " (7) Small containers If:",
        " 9 Information to be included on the main label"
    ]
}
{
    "path": [
        903030000,
        101000000,
        601290000,
        907040000,
        802000000
    ],
    "contexts": [
        " (c) if the medicine is: (i) supplied in either a small or a medium container; and (ii) contains multiple active ingredients then, in relation to compliance of the label with paragraph 9(3)(a), the names of the multiple active ingredients and their quantities may be presented together on a continuous line, or lines, of text.",
        "Introduction ",
        "\"homoeopathic potency\" means the dilution factor of a homoeopathic preparation, expressed as: (a) (b) \\\"nX\\\" where each dilution is a decimal or ten-fold dilution and \\\"n\\\" is the number of dilutions such that the total dilution is 10n; or \\\"nC\\\" where each dilution is a centesimal or hundred-fold dilution and \\\"n\\\" is the number of dilutions such that the total dilution is 100n; or (c) \\\"nLM\\\" or \\\"LMn\\\" where, from a 3C starting dilution, each subsequent dilution is a fifty millesimal or fifty thousand fold dilution and \\\"n\\\" is the number of dilutions such that the total dilution is 50,000^n. Note: Where 1000 centesimal dilutions are performed, the potency is expressed as nM; that is, 1M potency represents a 1,000C dilution, 2M a 2,000C dilution, etc",
        " (d) if subsection 8(2) applies and the medicine: (i) includes one or more active ingredients, the name of which includes descriptors (for example chemical salts or hydration states) that are not therapeutically relevant; and (ii) the name and quantity or proportion of each of those active ingredients is displayed in accordance with subsection 8(2), then the name of the therapeutically active moiety(ies) of the active ingredient may be displayed on the main label on the primary pack, instead of the name of the active ingredient, if: (iii) this is in a text size of not less than 3.0 millimetres; and (iv) no quantity or proportion information is displayed for any of the active ingredients in the medicine.",
        " (2)"
    ]
}
{
    "path": [
        700000000,
        1102050000,
        1008030000,
        1009020000,
        800000000
    ],
    "contexts": [
        " 7 General requirements, including label presentation",
        " (e) for a transdermal patch, as the total quantity of the active ingredient in each patch and the quantity of the active ingredient released in a stated time;",
        " (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.",
        " (b) If, in relation to a medicine referred to in (a) there are: (i) four or more active ingredients in the medicine and the medicine is intended to be, or is, registered goods; or (ii) two or more active ingredients in the medicine and the medicine is intended to be, or is, listed goods, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iii) the name of the medicine; and (iv) the batch number of the medicine preceded by the batch number prefix; and (v) the expiry date of the medicine preceded by the expiry date prefix; and (vi) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
        " 8 Information to be included on the label"
    ]
}
{
    "path": [
        601570000,
        601100000,
        802000000,
        802050000,
        802020000
    ],
    "contexts": [
        "\"stated volume of fill\" means the volume of medicine that the container is specified by the sponsor to contain;",
        "\"Certificate of Listing\", in relation to a medicine, means the certificate given to the applicant for listing of the medicine under subsection 26(4) or subsection 26A(9) of the Act in relation to that medicine;",
        " (2)",
        " (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details.",
        " (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information."
    ]
}
{
    "path": [
        904000000,
        501010000,
        601600001,
        910000000,
        909000000
    ],
    "contexts": [
        " (4) All text required by this Order to be on the main label must be oriented in the same direction.",
        "(a) intended for use in the treatment of another person in accordance with an approval set out in paragraph 19(1)(a) of the Act; or",
        "(a) any labelling requirements specified in the instrument made by the Minister under subsection 3(5A) of the Act, as in force from time to time; Note These requirements apply to all medicines other than those described in Part 1 of Schedule 10 to the Therapeutic Goods Regulations 1990",
        " (10) Subsection 9(9) does not apply:",
        " (9) If the medicine is intended to be, or is, registered goods, and the name of an active ingredient included in the medicine comprises an ingredient name specified in Schedule 2 to this Order, either alone or in combination with any other descriptors, then the names of all active ingredients in the medicine, together with their quantity or proportion, must be displayed in a text size of not less than 2.5 millimetres."
    ]
}
{
    "path": [
        601260000,
        801040000,
        601010000,
        908040000,
        906020000
    ],
    "contexts": [
        "\"herbal material\" means a plant or part of a plant (defined by its botanical scientific name according to the binominal nomenclature system, including author, and the plant part), whether fresh or dried, that is whole, fragmented, cut or ground;",
        " (d) the name of the dosage form; and",
        "\"Act\" means the Therapeutic Goods Act 1989;",
        " (d) the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit.",
        " (b) if there are four or more active ingredients in the medicine - the name of every active ingredient, together with the quantity or proportion of every active ingredient, may appear on a side panel or side label or on a rear panel or rear label."
    ]
}
{
    "path": [
        601140000,
        1001000000,
        907020000,
        908030000,
        907000000
    ],
    "contexts": [
        "\"container\" has the same meaning as in the Act;",
        " (1) Preparations for ophthalmic use In addition to the requirements of sections 8 and 9 above, if a medicine is a preparation for ophthalmic use, the label on the container and on the primary pack or, where subsection 10(7) applies, the primary pack, must include:",
        " (b) where the medicine contains four or more active ingredients and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or",
        " (c) (i) the total number of active ingredients in the different formulations in the composite pack or medicine kit are to be counted; and (ii) if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately, for the purposes of determining if paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit; and",
        " (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then:"
    ]
}
{
    "path": [
        908000000,
        1007070000,
        1005010000,
        1102080000,
        1102040000
    ],
    "contexts": [
        " (8) Where a medicine is:",
        " (g) the name of the dosage form; and",
        " (a) the medicine is a sunscreen preparation; and",
        " (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.",
        " (d) for a medicine required to be prepared before use, and: (i) where the process results in a medicine that is a liquid for ingestion: (A) as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid after preparation in accordance with the instructions set out on the label of the medicine; or (B) in the case where the medicine is one of a series of strengths containing the same active ingredient - as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid after preparation in accordance with the instructions set out on the label of the medicine with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume; and Example: Where the dose volume is 5 mL after preparation, and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labelled as 5 mg in 5 mL and 25 mg in 5 mL, respectively. (ii) for any other medicines - as the weight or volume of active ingredient in a stated weight or volume of the medicine, after preparation in accordance with the instructions included in the label of the medicine;"
    ]
}
{
    "path": [
        101000000,
        601070000,
        905020000,
        1009020000,
        900000000
    ],
    "contexts": [
        "Introduction ",
        "\"batch number prefix\" means the prefix which precedes the batch number and has the following characteristics: (a) clearly indicates that the information following the prefix is the batch number; and (b) is in the following form: \\\"BATCH NUMBER\\\", \\\"BATCH NO.\\\", \\\"BATCH\\\", \\\"B\\\", \\\"(B)\\\", \\\"B\/N\\\", \\\"LOT NUMBER\\\", \\\"LOT NO.\\\", or \\\"LOT\\\", or words or symbols to this effect, including a mixture of lower and upper case letters;",
        " (b) at least two of those active ingredients belong to any of the following categories: (i) a vitamin that is identified by both: (A) the approved name of the active ingredient that is a vitamin; and (B) in accordance with subsection 11(5), the word \u2018vitamin\u2019, or any suitable unambiguous abbreviation of the word vitamin, together with the common name of that vitamin; or (ii) a mineral;  (iii) a herbal preparation that, under subparagraph 11(2)(i)(ii), is required to be quantified as either: (A) the dry or fresh weight of herbal material from which the preparation was derived; or (B) the minimum dry or fresh weight of herbal material from which the preparation was derived, then: the names, and quantities or proportions, of all active ingredients in the medicine may appear on a side panel or side label or on a rear panel or rear label instead of on the main label; and",
        " (b) If, in relation to a medicine referred to in (a) there are: (i) four or more active ingredients in the medicine and the medicine is intended to be, or is, registered goods; or (ii) two or more active ingredients in the medicine and the medicine is intended to be, or is, listed goods, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iii) the name of the medicine; and (iv) the batch number of the medicine preceded by the batch number prefix; and (v) the expiry date of the medicine preceded by the expiry date prefix; and (vi) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
        " 9 Information to be included on the main label"
    ]
}
{
    "path": [
        601150000,
        601330000,
        400000000,
        905030000,
        802000000
    ],
    "contexts": [
        "\"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
        "\"listed goods\" has the same meaning as in the Act;",
        "4 Transition arrangements ",
        " (c) if the medicine is intended to be, or is, registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.",
        " (2)"
    ]
}
{
    "path": [
        601170000,
        402000000,
        601300000,
        907030000,
        901020000
    ],
    "contexts": [
        "\"dial dispenser pack\" means a container that has the following characteristics: (a) (b) (c) each of the dosage units is located in individual pockets preformed in a circular rigid tray; a close-fitting, rotatable, transparent lid which can only be rotated in one direction is located over the tray; and the individual dosage units can be dispensed by detaching a predefined portion of the lid or tray, and rotating the lid to the appropriate position;",
        "(2) On and from 1 September 2020, each medicine to which this Order applies must comply with the requirements specified in this Order.",
        "\"homoeopathic preparation\" has the same meaning as in the Regulations.",
        " (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or",
        " (b) the name(s) of all active ingredients in the medicine; and"
    ]
}
{
    "path": [
        908040000,
        601430105,
        501130000,
        601150000,
        801030000
    ],
    "contexts": [
        " (d) the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit.",
        "(v) the pack size;",
        "(m) made up or compounded extemporaneously, for a specific and individual case, by a complementary healthcare practitioner in the lawful practice of his or her profession; or",
        "\"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
        " (c) the quantity or proportion of all active ingredients in the medicine; and"
    ]
}
{
    "path": [
        1004010000,
        501050000,
        702050000,
        1103030000,
        1103010000
    ],
    "contexts": [
        " (a) the main label on the container and the main label on the primary pack (if any) must include a statement to the effect that the medicine contains homoeopathic preparations in text size that is not less than 50% of the text size of the name of the medicine and (in any event) not less than 2 millimetres;",
        "(e) the subject of an approval under section 19A of the Act; or",
        " (e) be in a colour or colours contrasting strongly with the background, except for:(i) the expiry date and expiry date prefix; and (ii) the batch number and batch number prefix when that information is embossed or debossed and not printed; and",
        " (c) where paragraphs (a) and (b) do not apply- the quantity of the preparation in one millilitre or in one gram of the medicine",
        " (a) where the medicine is a fully potentised, single ingredient, homoeopathic medicine and it is clear that the ingredient comprises 100% of the medicine \u2013 the name of the active ingredient; or"
    ]
}
{
    "path": [
        1007120000,
        100000002,
        912000000,
        802030000,
        802020000
    ],
    "contexts": [
        " (l) if the medicine is contained in an ampoule - a statement of the approved route of administration for the medicine, such as \u2018inhalation\u2019, \u2018For oral use only\u2019 or other phrase, word or abbreviation denoting the approved route(s) of administration of the medicine; and",
        "Uncommenced amendments The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.",
        " (12) To avoid doubt, an active ingredient specified in Part 1 of Schedule 2 must be included on the main label of a medicine containing that ingredient in accordance with the Australian Approved Names List for medicine released for supply on or after 1 May 2026.",
        " (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order.",
        " (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information."
    ]
}
{
    "path": [
        601500000,
        601130000,
        1105020000,
        802050000,
        802040000
    ],
    "contexts": [
        "\"Regulations\" means the Therapeutic Goods Regulations 1990;",
        "\"composite pack\" has the same meaning as in the Act;",
        " (b) on a separate line of text - immediately below the related name of the active ingredient that is a vitamin and the quantity of that active ingredient.",
        " (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details.",
        " (d) The information provided under paragraph 8(2)(b)(iii) may include safety related information not required by this Order (such as allergen advice, caution, additional warning or advisory statements)."
    ]
}
{
    "path": [
        601270000,
        601100000,
        1102020000,
        1102080000,
        1102020000
    ],
    "contexts": [
        "\"herbal preparation\" means an ingredient that is the result of the processing of a herbal material;",
        "\"Certificate of Listing\", in relation to a medicine, means the certificate given to the applicant for listing of the medicine under subsection 26(4) or subsection 26A(9) of the Act in relation to that medicine;",
        " (b) for a solid for ingestion, where there is no discrete dosage unit - as the quantity of the active ingredient contained in the stated weight of a suitable dose of the solid;",
        " (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.",
        " (b) for a solid for ingestion, where there is no discrete dosage unit - as the quantity of the active ingredient contained in the stated weight of a suitable dose of the solid;"
    ]
}
{
    "path": [
        801130000,
        0,
        601430100,
        301000000,
        400000000
    ],
    "contexts": [
        " (m) if the medicine requires some preparation, such as dissolving, suspending, diluting or reconstituting before use - instructions for its preparation and, where relevant, a statement of the conditions of storage and the maximum period of storage between preparation and use, except where: (i) there is insufficient space on the label of either the container or the primary pack, or both, to include this information; and (ii) this information is set out in a package insert provided in the primary pack of the medicine; and (iii) a statement is included on whichever label on the container or the primary pack, or both, that does not set out the information itself, that this information is set out in the package insert; and",
        " Therapeutic Goods Order No. 92 - Standard for labels of non-prescription medicines",
        "(a) where the medicine is intended to be, or is, entered in the Register - the name of the medicine intended to appear or appearing on the Certificate of Registration or Certificate of Listing in relation to the medicine, not including the following information:",
        "(1) Subject to sections 4 and 5, this Order applies to medicines supplied or for supply in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91 \u2013 Standard for labels of prescription and related medicines.",
        "4 Transition arrangements "
    ]
}
{
    "path": [
        100000004,
        1101030000,
        1008030000,
        1008020000,
        900000000
    ],
    "contexts": [
        "Modifications If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.",
        " (c) Where the active ingredient is in liquid form, the equivalent metric units of volume must be expressed in the same manner. Example: A statement of volume for more than 1 millilitre up to 999 millilitres inclusive must be expressed in terms of millilitres, but a statement of volume for 1000 millilitres may be expressed as either 1000 millilitres or 1 litre. Note: The abbreviations mL and L can be used on all labels, but \\'microlitre\\' should be used in full unless the container is a small container. Then the abbreviation \\'\uf06d L\\' may be used.",
        " (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.",
        " (b) If: (i) the medicine consists only of pastilles or lozenges; and (ii) each dosage unit is enclosed in an unsealed individual wrapper; and (iii) each dosage unit is, after being so wrapped, enclosed in a primary pack that complies with sections 8 and 9, then, in relation to compliance of the label for each individual wrapper with sections 8 and 9, it shall be sufficient if the name of the medicine is displayed.",
        " 9 Information to be included on the main label"
    ]
}